Literature DB >> 8161625

Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.

C C John1.   

Abstract

Recent reports have documented the increasing number of pneumococcal isolates that are relatively or completely resistant to penicillin and other antibiotics. This report documents a case in which third-generation cephalosporin failed in the treatment of pneumococcal meningitis and reviews the clinical and microbiological features of the seven similar cases reported to date. In all eight cases, the pneumococci were penicillin resistant. Taken together, these cases suggest that (1) children with intermediately penicillin-resistant pneumococcal meningitis (MIC, 0.1-1.0 micrograms/mL) who are treated with cefotaxime or ceftriaxone should be observed carefully for treatment failure and (2) children with highly penicillin-resistant pneumococcal meningitis (MIC, > or = 2.0 micrograms/mL) are best treated with vancomycin and rifampin until the MICs of cefotaxime and ceftriaxone for the pneumococcus are known.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161625     DOI: 10.1093/clinids/18.2.188

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Bacterial Meningitis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

3.  The emergence of resistant pneumococcal meningitis--implications for empiric therapy.

Authors:  P McMaster; P McIntyre; R Gilmour; L Gilbert; A Kakakios; C Mellis
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

4.  Clinical implication of extended-spectrum cephalosporin nonsusceptibility in Streptococcus pneumoniae meningitis.

Authors:  S-H Choi; J-W Chung; B-N Kim; Y G Kwak; T H Kim; E J Lee; E J Choo; M-H Jeon; M S Lee; I-G Bae; S-R Lee; E H Song; J-B Jun; M-N Kim; S-H Kim; S-O Lee; Y S Kim; J H Woo; S-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-02       Impact factor: 3.267

5.  Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.

Authors: 
Journal:  Paediatr Child Health       Date:  2001-03       Impact factor: 2.253

6.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 7.  The new threats of Gram positive pathogens: re-emergence of things past.

Authors:  R A Howe; N M Brown; R C Spencer
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

8.  Evaluation of commercial methods for determining antimicrobial susceptibility of Streptococcus pneumoniae.

Authors:  F C Tenover; C N Baker; J M Swenson
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

9.  Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.

Authors:  D P Nicolau; P R Tessier; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

10.  Prevention of Pneumococcal Meningitis.

Authors:  Tina Q. Tan
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.